|View printer-friendly version|
|October 12, 2003 4:46 p.m.|
|Teva And Lundbeck Announce European Submission Of Rasagiline As A Treatment For Parkinson's Disease|
Jerusalem, Israel, October 12, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and H. Lundbeck A/S (CSE: LUN.CO) announced today that the rasagiline regulatory file has been submitted to the European Agency for Evaluation of Medicinal Products (EMEA) for the treatment of Parkinson's disease (PD). This submission is based on data from three Phase III clinical trials which included over 1500 PD patients, and follows the recent U.S. and Canadian submissions.